SYNTAX II: CABG-LIKE OUTCOMES WITH SYNERGY™ BP STENT AND STATE-OF-THE-ART PCI STRATEGY

The SYNTAX II Trial evaluated the SYNERGY™ BP-EES Stent in a procedure-related trial involving a multitude of variables when treating patients with three-vessel disease including:

PHYSIOLOGY
physiological assessment of the lesion and vessel

TREATMENT
use of an advanced generation thin strut BP-EES with abluminal coating

CROSSING
contemporary CTO techniques

STENT OPTIMIZATION
IVUS guidance for optimal DES implantation

The 12 month results were then compared to the PCI and CABG arms of the original SYNTAX I Trial as historical comparators. So what did we learn?

PHYSIOLOGY

We learned that the right patients were treated for the right reasons when physiology (FFR/iFR) is utilized.

Use of physiology assessment resulted in deferring of intervention in **31%** of patients





CROSSING



We learned that contemporary CTO PCI in SYNTAX II Trial demonstrated a significantly higher procedural success rate compared to those in SYNTAX I.

PCI with CTO procedural success rates jumped from **53% in SYNTAX I to 87% in SYNTAX II.** That represents a **64% increase in successful CTO treatment.**

TREATMENT

We learned that SYNERGY™ BP-EES together with other contemporary technologies and techniques proved PCI could be an option for patients with complex three-vessel disease.

Low rates of revascularization, peri-procedural MI and acute ST suggest that SYNERGY BP-EES might help in reducing procedural related complications.

SYNTAX I and SYNTAX II ARC Def. ST Comparisons:

0.7% (74% relative risk reduction)

SYNTAX I PCI Arm: 2.7%
SYNTAX II: 0.7%
$p = 0.045$

MACCE Comparisons:

10.6%

SYNTAX I MACCE CABG arm: 11.2%
SYNTAX II MACCE: 10.6%
$p = 0.684$

STENT OPTIMIZATION



We learned that IVUS helps to optimize stent placement and achieve better outcomes when used as a part of contemporary PCI.

Post-Implantation IVUS was performed in **84% of patients** leading to further stent optimization in **30% of lesions.**

SYNTAX II shows that physiological assessment, contemporary CTO techniques, use of the SYNERGY BP-EES Stent, and IVUS guidance demonstrate CABG-like outcomes in patients with three-vessel disease. Boston Scientific has a minimally-invasive complete revascularization portfolio to address these needs for patients. Contact a rep today for more information.

Boston Scientific
Advancing science for life™